Cost-effectiveness of a chronic pain intervention for people living with HIV (PLWH)

dc.contributor.authorMerlin, Jessica S.
dc.contributor.authorWestfall, Andrew O.
dc.contributor.authorJohnson, Mallory O.
dc.contributor.authorKerns, Robert D.
dc.contributor.authorBair, Matthew J.
dc.contributor.authorKertesz, Stefan
dc.contributor.authorTuran, Janet M.
dc.contributor.authorClay, Olivio J.
dc.contributor.authorStarrels, Joanna L.
dc.contributor.authorKilgore, Meredith
dc.contributor.departmentMedicine, School of Medicineen_US
dc.date.accessioned2018-04-12T14:20:27Z
dc.date.available2018-04-12T14:20:27Z
dc.date.issued2018
dc.description.abstractBackground: Chronic pain is a common, disabling, and costly comorbidity, particularly in people living with HIV (PLWH). This study developed and pilot tested a pain self-management intervention for chronic pain tailored to PLWH called Skills TO Manage Pain (STOMP). Objectives: Given the additional resources needed to deliver STOMP in HIV clinical settings, an important objective of the pilot study was to assess not only STOMP’s preliminary efficacy, but also its cost-effectiveness. Research design and subjects: The present study draws from a 44-participant, 2-arm randomized pilot trial of the STOMP intervention vs usual care among PLWH and at least moderate chronic pain (Clinicaltrials.gov: NCT02824562). Cost-effectiveness is presented as the incremental cost-effectiveness ratio (ICER). Costs were considered from the clinic perspective over a 1-year time horizon using real costs from the pilot trial. It was conservatively assumed there would be no costs savings. The Standard Gamble (SG) method was used to directly measure utilities. Results: Thirty-six participants met inclusion criteria for the present analyses. Mean age was 52 years; 61% were female and 86% were black. The total cost of STOMP was $483.83 per person. Using the SG method, the change in QALYs was 0.15, corresponding to an ICER of $3,225. Conclusions: STOMP’s cost/QALY is substantially lower than the $50,000 to $100,000/QALY benchmark often used to indicate cost-effectiveness. Although based on a pilot trial and, therefore, preliminary, these findings are promising, and suggest the importance of cost analyses in future STOMP trials.en_US
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationMerlin, J. S., Westfall, A. O., Johnson, M. O., Kerns, R. D., Bair, M. J., Kertesz, S., … Kilgore, M. (2018). Cost-effectiveness of a chronic pain intervention for people living with HIV (PLWH). Journal of Medical Economics, 21(2), 122–126. https://doi.org/10.1080/13696998.2017.1377719en_US
dc.identifier.urihttps://hdl.handle.net/1805/15841
dc.language.isoenen_US
dc.publisherTaylor & Francisen_US
dc.relation.isversionof10.1080/13696998.2017.1377719en_US
dc.relation.journalJournal of Medical Economicsen_US
dc.rightsPublisher Policyen_US
dc.sourceAuthoren_US
dc.subjectself-managementen_US
dc.subjectpainen_US
dc.subjectcost-effectivenessen_US
dc.titleCost-effectiveness of a chronic pain intervention for people living with HIV (PLWH)en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Merlin_2017_cost.pdf
Size:
195.17 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: